A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae by Pascual Hernández, Álvaro et al.
A Multinational, Preregistered Cohort Study of -Lactam/-Lactamase
Inhibitor Combinations for Treatment of Bloodstream Infections Due
to Extended-Spectrum--Lactamase-Producing Enterobacteriaceae
Belén Gutiérrez-Gutiérrez,a Salvador Pérez-Galera,a Elena Salamanca,a Marina de Cueto,a Esther Calbo,b Benito Almirante,c
Pierluigi Viale,d Antonio Oliver,e Vicente Pintado,f Oriol Gasch,g Luis Martínez-Martínez,h Johann Pitout,i Murat Akova,j
Carmen Peña,k José Molina,a Alicia Hernández,l Mario Venditti,m Nuria Prim,n Julia Origüen,o German Bou,p Evelina Tacconelli,q
Mario Tumbarello,r Axel Hamprecht,s Helen Giamarellou,t Manel Almela,u Federico Pérez,v Mitchell J. Schwaber,w Joaquín Bermejo,x
Warren Lowman,y Po-Ren Hsueh,z Marta Mora-Rillo,aa Clara Natera,bb Maria Souli,cc Robert A. Bonomo,v,dd Yehuda Carmeli,w
David L. Paterson,ee Alvaro Pascual,a,ff Jesús Rodríguez-Baño,a,gg the REIPI/ESGBIS/INCREMENT Group
Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Rocío—IBIS, Seville,
Spaina; Hospital Universitari Mútua de Terrassa, Barcelona, Spainb; Hospital Universitari Vall d’Hebrón, Barcelona, Spainc; Teaching Hospital Policlinico S. Orsola Malpighi,
Bologna, Italyd; Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spaine; Hospital Ramón y Cajal, Madrid, Spainf;
Corporacio Sanitaria Parc Taulí, Sabadell, Barcelona, Spaing; Hospital Universitario Marqués de Valdecilla—IDIVAL, Santander, Spainh; Department of Medicine, University
of Calgary, Calgary, Canadai; Hacettepe University School of Medicine, Ankara, Turkeyj; Hospital Universitari de Bellvitge, Barcelona, Spaink; Hospital Universitario Virgen de
la Arrixaca, Murcia, Spainl; Policlinico Umberto I, University of Rome La Sapienza, Rome, Italym; Hospital de la Santa Creu i Sant Pau, Barcelona, Spainn; Hospital
Universitario 12 de Octubre, Madrid, Spaino; Complejo Hospitalario Universitario A Coruña, A Coruña, Spainp; Universitätsklinikum Tübingen, Tübingen, Germanyq;
Catholic University of the Sacred Heart, Rome, Italyr; Institut für Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Köln, Cologne, Germanys; Hygeia General
Hospital, Athens, Greecet; Hospital Clinic, Barcelona, Spainu; Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio,
USAv; Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, and National Center for Infection Control, Israel Ministry of
Health, Tel Aviv, Israelw; Hospital Español, Rosario, Argentinax; Wits Donald Gordon Medical Centre, Johannesburg, South Africay; National Taiwan University Hospital,
National Taiwan University College of Medicine, Taipei, Taiwanz; Hospital Universitario La Paz—IdiPAZ, Madrid, Spainaa; Hospital Universitario Reina Sofia-IMIBIC-UCO,
Córdoba, Spainbb; University General Hospital Attikon, Chaidari, Greececc; Departments of Medicine, Pharmacology, Biochemistry, Molecular Biology, and Microbiology,
Case Western Reserve University School of Medicine, Cleveland. Ohio, USAdd; University of Queensland Centre for Clinical Research, The University of Queensland,
Herston, Brisbane, Australiaee; Departamento de Microbiología, Universidad de Sevilla, Seville, Spainff; Departamento de Medicina, Universidad de Sevilla, Seville, Spaingg
The spread of extended-spectrum--lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbap-
enem consumption. Alternatives to carbapenems need to be investigated. We investigated whether -lactam/-lactamase inhibi-
tor (BLBLI) combinations are as effective as carbapenems in the treatment of bloodstream infections (BSI) due to ESBL-E. A
multinational, retrospective cohort study was performed. Patients with monomicrobial BSI due to ESBL-E were studied; specific
criteria were applied for inclusion of patients in the empirical-therapy (ET) cohort (ETC; 365 patients), targeted-therapy (TT)
cohort (TTC; 601 patients), and global cohort (GC; 627 patients). The main outcome variables were cure/improvement rate at
day 14 and all-cause 30-day mortality. Multivariate analysis, propensity scores (PS), and sensitivity analyses were used to control
for confounding. The cure/improvement rates with BLBLIs and carbapenems were 80.0% and 78.9% in the ETC and 90.2% and
85.5% in the TTC, respectively. The 30-day mortality rates were 17.6% and 20% in the ETC and 9.8% and 13.9% in the TTC, re-
spectively. The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate with ET with BLBLIs
were 1.37 (0.69 to 2.76); for TT, they were 1.61 (0.58 to 4.86). Regarding 30-day mortality, the adjusted OR (95% CI) values were
0.55 (0.25 to 1.18) for ET and 0.59 (0.19 to 1.71) for TT. The results were consistent in all subgroups studied, in a stratified analy-
sis according to quartiles of PS, in PS-matched cases, and in the GC. BLBLIs, if active in vitro, appear to be as effective as carbap-
enems for ET and TT of BSI due to ESLB-E regardless of the source and specific species. These data may help to avoid the overuse
of carbapenems. (This study has been registered at ClinicalTrials.gov under registration no. NCT01764490.)
The spread of extended-spectrum -lactamases (ESBLs) in En-terobacteriaceae (ESBL-E) has become a serious public health
problem worldwide (1–3). Carbapenems are considered the drugs
of choice for treating severe infections caused by ESBL producers
according to observational studies (1–3). This is leading to an
increased consumption of carbapenems, which is particularly
worrisome in a scenario where carbapenemase-producing organ-
isms are spreading rapidly (4, 5). The search for alternatives to
carbapenems for infections caused by ESBL producers is therefore
a clinical priority.
ESBLs are inhibited by -lactamase inhibitors (1). Although
hyperproduction of -lactamases or additional resistance
mechanisms may hamper the activity of these compounds,
-lactam/-lactamase inhibitor combinations (BLBLIs) such
as amoxicillin-clavulanate (AMC) or piperacillin-tazobactam
(PTZ) remain active against a considerable proportion of
ESBL-E in many areas of the world (6–11). However, the effi-
cacy of BLBLIs for treating serious infections caused by ESBL-E
is controversial (11–13).
Designing and executing observational studies comparing the
efficacy of different antimicrobials for infections caused by mul-
tidrug-resistant bacteria presents specific challenges. In fact, most
studies published to date in this field have important drawbacks
that seriously challenge their validity; some recommendations for
improving the quality of observational studies in this field have
been published (14).
crossmark
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We hypothesize that BLBLIs are noninferior to carbapenems
for the treatment of bloodstream infections (BSI) due to ESBL-E,
regardless of the source of the BSI or the Enterobacteriaceae spe-
cies. Using advanced observational methods and an international
effort, the objective of this study was to evaluate whether BLBLIs
were as efficacious as carbapenems for the treatment of BSI due to
diverse ESBL-E from different sources.
MATERIALS AND METHODS
Study design and patients. The INCREMENT project (ClinicalTrials.gov
identification no. NCT01764490) is a retrospective international cohort
study including consecutive patients with clinically significant BSI due to
ESBL- or carbapenemase-producing Enterobacteriaceae from January
2004 to December 2013. The overall objective of INCREMENT is to eval-
uate the efficacy of different antimicrobial drugs and regimens; 37 tertiary
hospitals from 12 countries experienced in identifying ESBL- or carbap-
enemase-producing Enterobacteriaceae and collecting data from patients
with BSI participated. This analysis was reported according to the
STROBE recommendations (see Table S1 in the supplemental material)
(15).
For this analysis and in accordance with the prespecified registered
plan, patients with clinically significant monomicrobial BSI due to
ESBL-E were included, provided that they received monotherapy with an
active BLBLI (AMC, PTZ, or ampicillin-sulbactam [AMS]) (including
those with intermediate susceptibility according to CLSI criteria [16]) or a
carbapenem (including imipenem, meropenem, doripenem, and ertap-
enem). Data for patients were collected from charts for up to 30 days after
the diagnosis of BSI; if needed, patients or relatives were contacted by
phone, and mortality registers were consulted.
We constructed 3 nonmutually exclusive cohorts in order to ana-
lyze the impact of empirical and targeted therapies (ET and TT, respec-
tively), as follows. The impact of empirical therapy was investigated in
the empirical-therapy cohort (ETC), which included the patients who
received monotherapy with either a BLBLI or a carbapenem that began
within the first 24 h after blood cultures were taken and continued for
at least 48 h (except for patients who died in 48 h, who were included
if they received at least 1 complete day of therapy). The impact of
targeted therapy was investigated in the targeted-therapy cohort
(TTC), which included the patients who received a BLBLI or a carbap-
enem as monotherapy once the susceptibility profile was available; the
targeted drug must have started in 5 days and been administered for
at least 50% of the total duration of therapy (except for patients who
died while on targeted therapy, who were included if they received at
least 1 complete day of therapy). Finally, the impact of maintaining or
changing the empirical therapy was investigated in the global cohort
(GC), which included any patient who received either empirical or
targeted monotherapy with a BLBLI or a carbapenem with the above
criteria if they survived for at least 72 h (and therefore had the possi-
bility of receiving targeted therapy). In the GC, the reference regimen
for comparison was empirical and targeted therapy with a carbap-
enem.
The INCREMENT project was approved by the Spanish Agency of
Medicines (AEMPS; code JRB-ANT-2012-01) and the Hospital Universi-
tario Virgen Macarena Institutional Review Board (code 1921); the need
to obtain written informed consent was waived. Approval was also ob-
tained at participating centers according to local requirements.
Variables and definitions. Data collected from all patients included
demographics, nosocomial or community acquisition, underlying condi-
tions and their severity using the McCabe classification (17), severity of
acute condition at BSI presentation according to the Pitt score (18),
source of BSI according to clinical and microbiological data, severe sepsis
or septic shock before administration of therapy (19), antimicrobial ther-
apy, clinical response, mortality, and length of stay after BSI. All time-
dependent variables were measured with regard to the day when the blood
cultures were drawn (considered day 0). Enterobacteriaceae were identi-
fied using standard microbiological techniques in each participating
center. ESBL production was screened in all isolates with diminished sus-
ceptibility to cephalosporins and confirmed according to standard proce-
dures; 2012 CLSI recommendations were used for susceptibility interpre-
tation (16). For isolates obtained before 2012, MICs were reviewed and
the susceptibility category was assigned accordingly; for 27 isolates (19
from patients treated with carbapenems and 8 from patients treated with
BLBLIs), the MIC was not available or the available data showed a MIC
equal to or below the older susceptibility breakpoint; these were consid-
ered susceptible if so reported by the local laboratory. Selected isolates
from each center had been characterized by PCR and DNA sequencing
using established methods. Nosocomial acquisition was considered when
infection symptoms started 48 h after hospital admission or within 48 h
of hospital discharge. Otherwise, the case was considered community on-
set. Times refer to the day when the blood culture that diagnosed BSI was
taken. Antimicrobial therapy administered before the susceptibility re-
sults were available was considered empirical; therapy administered there-
after was considered targeted. Therapy with a BLBLI or a carbapenem was
considered monotherapy if no other drug with intrinsic activity against
Gram-negative organisms—including penicillins, cephalosporins,
monobactams, fluoroquinolones, aminoglycosides, trimethoprim-sulfa-
methoxazole, fosfomycin, and colistin—was coadministered, irrespective
of isolate susceptibility.
The main outcome variables were clinical response at day 14 and 30-day
mortality. Clinical response was classified as cure, improvement, or failure.
Clinical cure was defined as the resolution of all signs and symptoms related to
the infection, with no further need for antibiotic therapy; improvement was
defined as partial control or resolution of signs and symptoms related to the
infection or complete resolution but continued on antibiotic therapy; and
failure was defined as a clinical situation qualified as similar to or worse than
the one at the bacteremia diagnosis or death due to any cause. Clinical re-
sponse was dichotomized as cure/improvement versus failure.
Statistical analysis. Separate analyses were performed for the 3 co-
horts. A propensity score (PS; the probability of receiving therapy with a
BLBLI) was calculated for each cohort as previously described (11); all the
models obtained for propensity scores had an area under the receiver
operating characteristic curve (AUROC) of 0.80. The PS was used in 3
ways: (i) as a covariate in multivariate analysis; (ii) to stratify the cohorts
according to quartiles of the PS; and (iii) to match patients so that each
patient who received treatment with a BLBLI was matched with one who
received treatment with a carbapenem using calipers of a width equal to
0.2 of the standard deviation of the logit of the propensity score.
Multivariate analyses for clinical response were performed using lo-
gistic regression to control for confounding. For mortality, because pro-
portional hazards assumptions were not fulfilled as shown by Kaplan-
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Meier plotting, a Cox regression analysis could not be performed, and
therefore, logistic regression was also used. Variables with P values of 0.2
in the bivariate analysis were introduced into models. Interactions be-
tween therapy with BLBLIs or carbapenems and other variables were ex-
plored and were included if they caused a significant modifying effect. The
Akaike information criterion (AIC) (20) was used to select the final models.
Sensitivity analyses were performed by investigating the effect of BLBLI versus
carbapenem therapy in specific subgroups of interest. The center effect was
analyzed by including individual or grouped centers in the multivariate anal-
ysis. Additionally, a meta-regression analysis considering the geographical
regions (Spain, other Mediterranean countries, and the rest of the world) was
performed; the odds ratios (OR) and 95% confidence intervals (CI) for mor-
tality in the geographical clusters and overall were calculated using a random
effect model. Comparisons of matched cohorts were performed by condi-
tional logistic regression. The analyses were performed using R software (ver-
sion 3.0.1) and SPSS 15.0 software.
RESULTS
The INCREMENT database includes 1,005 patients with BSI
due to ESBL-E. Two hundred seventy-eight patients did not
fulfil the criteria for inclusion in this analysis; 22 of them were
excluded because they died before receiving at least one com-
plete day of therapy. Eleven of them were treated with BLBLIs
(10 with PTZ and 1 with AMC), and 11 with carbapenems (10
with meropenem and 1 with imipenem). Including these pa-
tients in the analysis did not change the results. Three hundred
sixty-five, 601, and 627 patients from 30 centers were included
in the ETC, TTC, and GC groups, respectively (see Fig. S1 in the
supplemental material). The number of cases per center in the
GC ranged from 4 to 50. A total number of 207 cases from the
GC were characterized by PCR amplification of blaESBL genes.
The most frequent ESBLs produced by the isolates were
CTX-M, in 160 cases (77.3%; 42 CTX-M-15, 27 CTX-M-1, 31
CTX-M-14, 18 CTX-M-9, 2 CTX-M-2, 1 CTX-M-1 and 39
nonspecified CTX-M enzymes), SHV-type in 22 cases (10.6%),
and TEM-type in 25 cases (12.1%).
Empirical-therapy cohort. The ETC included 365 patients:
170 received empirical therapy with a BLBLI (PTZ in 123 cases,
AMC in 45, and AMS in 2), and 195 with a carbapenem (mero-
penem in 128 cases, imipenem in 35, and ertapenem in 32).
Among the 172 patients treated empirically with PTZ, the isolate
was susceptible to this antibiotic in 126 (73.2%); this was the case
for 41 of 68 (60.3%) receiving AMC and for 3 of 10 (30%) receiv-
ing AMS. The isolates were susceptible to carbapenems in all pa-
tients treated with these antimicrobials.
The characteristics of patients by treatment type are shown in
Table 1. The most frequent dose regimens were as follows: for
PTZ, 4 g piperacillin/0.5 g tazobactam every 8 h (4/0.5 g q8h)
(47% of patients) and 4/0.5 g q6h (18%); for AMC, 1/0.2 g q8h
(73.6%); for imipenem, 0.5 g q6h (40%) and 0.5 g q8h (29%); for
meropenem, 1 g q8h (65%) and 1 g q12h (20%); and for ertap-
enem, 1 g q24h (84%). The cure/improvement rates at day 14 were
78.9% for carbapenems and 80.0% for BLBLIs (absolute differ-
ence, 1.0%; 95% CI, 7.3% to 9.2%; P  0.81). The univariate
analysis of variables associated with cure/improvement is shown
in Table S2 in the supplemental material.
The PS-adjusted OR of empirical therapy with BLBLIs for
cure/improvement was 1.03 (95% CI, 0.54 to 1.96; P  0.9); when
other potential confounders were added, including targeted ther-
apy, the adjusted OR was 1.37 (95% CI, 0.69 to 2.76; P  0.37)
(Table 2). The addition of individual or grouped centers did not
change the results. The sensitivity analysis in specific subpopula-
tions (Fig. 1A) showed that the effects of empirical therapy with
BLBLIs were similar irrespective of etiology, presentation with
severe sepsis or shock, source, or specific antibiotics used.
The mortality rates among patients empirically treated with
carbapenems versus BLBLIs were similar (20% versus 17.6%; abso-
lute difference at day 30, 2.4%; 95% CI, 10.2% to 5.80%;
P  0.6 by log-rank test) (Fig. 2A and Table 1). Univariate analysis
of variables associated with 30-day mortality is shown in Table
S3 in the supplemental material. The PS-adjusted OR of em-
pirical therapy with BLBLIs for 30-day mortality was 0.72 (95%
CI, 0.37 to 1.38; P  0.32). When other potential confounders
were added, it was 0.55 (95% CI, 0.25 to 1.18; P  0.14) (Table
3). A meta-regression analysis considering the geographical regions
(Spain, other Mediterranean countries, and the rest of the world) did
not show significant differences between BLBLIs and carbapenems
(see Table S4 and Fig. S2).
We then performed a stratified analysis according to the quartiles
of the PS; no significant differences in cure/improvement or mortal-
ity rates were shown, but it should be noted that the number of cases
treated empirically with BLBLIs in the first stratum was low (Table 4).
Finally, we performed a PS-based matched analysis; we could match
100 pairs of patients treated empirically with BLBLIs or carbapenems
according to the PS; the matched patients did not show significant
differences in exposure to variables related to empirical therapy (see
Table S5 in the supplemental material); the cure/improvement and
mortality rates among patients treated empirically with BLBLIs or
carbapenems were 78% and 77% (P  0.87) and 17% and 23% (P 
0.29), respectively; the Kaplan-Meier curves for survival in propensity
score-matched patients are shown in Fig. S3.
Targeted-therapy cohort. The TTC included 601 patients: 92
received targeted therapy with a BLBLI (32 AMC and 60 PTZ),
and 509 received a carbapenem (205 ertapenem, 185 meropenem,
118 imipenem, and 1 doripenem). The characteristics of patients
by treatment type are shown in Table 1. The most frequent dose
regimens were as follows: for PTZ, 4/0.5 g q6h (40.0%) and 4/0.5
g q8h (43.3%); for AMC, 1/0.2 g q8h (59.4%) and 2/0.5 g q8h
(12.5%); for imipenem, 0.5 g q6h (49.1%) and 0.5 g q8h (20.3%);
for meropenem, 1 g q8h (50.8%), 1 g q12h (15.1%) and 1 g q24h
(9.2%); and for ertapenem, 1 g q24h (84.3%).
The cure/improvement rates at day 14 were 90.2% and 85.5%
for carbapenems and BLBLIs, respectively (P  0.22; absolute
difference, 4.7%; 95% CI, 3.5% to 10.3%). Univariate analysis of
variables associated with cure/improvement is shown in Table S6
in the supplemental material.
The PS-adjusted OR of targeted therapy with BLBLIs for cure/
improvement was 1.39 (95% CI, 0.55 to 3.82; P  0.44); when other
potential confounders were added, the adjusted OR was 1.61 (95%
CI, 0.58 to 4.86; P  0.38) (Table 2). The addition of individual or
grouped centers did not change the results. The results of sensitivity
analysis in specific subpopulations are shown in Fig. 1B and showed
no trend for different outcomes; some subpopulations, including pa-
tients with etiology other than Escherichia coli, patients with urinary
source only, and AMC-treated patients only in the BLBLI group, were
not considered due to very low numbers of events.
The mortality rates among patients who received targeted ther-
apy with carbapenems or BLBLIs were similar (9.8% versus
13.9%; absolute difference at day 30, 2.4%; 95% CI, 10.2% to
5.80%; P  0.28 by log-rank test) (Fig. 2B and Table 1). Univariate
analysis of variables associated with 30-day mortality is shown in
-Lactam/-Lactamase Inhibitor Combinations in ESBL-E
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Table S7 in the supplemental material. The PS-adjusted OR of
targeted therapy with BLBLIs for 30-day mortality was 0.65 (95%
CI, 0.23 to 1.65; P  0.86). When other potential confounders
were added, it was 0.59 (95% CI, 0.19 to 1.71; P  0.35) (Table 3).
Meta-regression analysis considering geographical regions did not
show significant differences (see Table S8 and Fig. S4).
The stratified analysis performed according to the quartiles of
the PS only had a meaningful number of patients for quartiles 3
and 4; in these, no significant differences in cure/improvement or
mortality rate were shown (Table 4). We could only match 55
pairs of patients receiving targeted treatment with BLBLIs or car-
bapenems according to the PS; the matched patients did not show
significant differences in exposure to variables related to therapy
(see Table S9 in the supplemental material); the cure/improve-
ment and mortality rates among patients treated with BLBLIs or
carbapenems were 89.1% and 83.6% (P  0.40) and 7.3% and
16.4% (P  0.14), respectively; the Kaplan-Meier curves for sur-
vival in propensity score-matched patients are shown in Fig. S5.
Global-therapy cohort. Overall, 627 patients were included in
the GTC; 156 received empirical and targeted therapy with a carbap-
enem, 152 received empirical therapy with a BLBLI and targeted ther-
apy with a carbapenem, 63 received empirical and targeted therapy
with a BLBLI, 225 received empirical therapy with a drug other than a
carbapenem or a BLBLI and targeted therapy with a carbapenem, and
31 received empirical therapy with a drug other than a carbapenem or
a BLBLI and targeted therapy with a BLBLI. The baseline features of
the patients in each group are shown in Table 5. The 14-day cure/
improvement rates were 87.7%, 85.5%, 87.3%, 84.9%, and 90.3%,
TABLE 1 Characteristics of patients with bloodstream infections caused by extended-spectrum--lactamase-producing Enterobacteriaceae in the
empirical- and targeted-therapy cohorts
Characteristic
No. (%) of patients (unless otherwise specified) in indicated group
Empirical-therapy cohort Targeted-therapy cohort
BLBLI (n  170)
Carbapenem
(n  195) P valuea BLBLI (n  92)
Carbapenem
(n  509) P valuea
Age [median (IQRb)] 71.5 (59–79) 66 (54.5–76) 0.005c 70.5 (56–80) 68 (56–78) 0.22c
Male sex 95 (55.9) 117 (60.0) 0.42 55 (59.8) 295 (58.0) 0.74
Enterobacteriaceae species
E. coli 130 (76.3) 136 (69.7) 0.15 71 (77.2) 368 (72.3) 0.33
K. pneumoniae 29 (17.1) 45 (23.1) 0.15 13 (14.1) 101 (19.8) 0.20
Other 11 (6.5) 14 (7.2) 0.79 8 (8.7) 40 (7.9) 0.78
Nosocomial acquisition 75 (44.1) 91 (46.7) 0.63 38 (41.3) 247 (48.5) 0.2
Source
Urinary tract 77 (45.3) 91 (46.7) 0.79 39 (42.4) 233 (45.8) 0.55
Biliary tract 25 (14.7) 24 (12.3) 0.5 9 (9.8) 62 (12.2) 0.51
Other (high-risk source) 68d (40.0) 80e (41.0) 0.84 44f (47.8) 214g (42.0) 0.30
ICUh admission 13 (7.6) 26 (13.3) 0.071 4 (4.3) 62 (12.2) 0.02
McCabe classification, nonfatal 81 (47.6) 95 (48.7) 0.84 47 (51.1) 263 (51.7) 0.92
Cancer 50 (29.4) 74 (37.9) 0.068 38 (41.3) 208 (40.9) 0.86
Pitt score [median (IQR)] 1 (0–3) 1 (0–3) 0.30c 1 (0–2) 1 (0–2) 0.19c
Severe sepsis or shock 67 (39.4) 72 (36.9) 0.86 31 (33.7) 164 (32.2) 0.94
Targeted therapy with:
Carbapenem 80 (47.1) 169 (86.7) 0.0001
BLBLI 65 (38.2) 8 (4.1) 0.0001
Other drug 25 (14.7) 18 (9.2) 0.11
Empirical therapy with:
Carbapenem 4 (4.3) 141 (27.7) 0.0001
BLBLI 56 (60.9) 140 (27.5) 0.0001
Other drug 32 (34.8) 228 (44.8) 0.07
Active empirical therapy 65 (70.7) 304 (59.7) 0.047
Cure/improvement 136 (80.0) 154 (79.0) 0.81 83 (90.2) 435 (85.5) 0.22
30-day mortality 30 (17.6) 39 (20.0) 0.60 9 (9.8) 71 (13.9) 0.28
a P values were calculated by 2 test, except where otherwise specified.
b IQR, interquartile range.
c Mann-Whitney U test.
d Other sources included unknown, 21; intra-abdominal, 20; pneumonia, 12; skin, 7; vascular, 7; other, 1.
e Other sources included unknown, 27; vascular, 19; intra-abdominal, 16; pneumonia, 10; skin, 5; other, 3.
f Intra-abdominal, 17; unknown, 13; vascular, 6; skin, 3.
g Unknown, 74; intra-abdominal, 51; vascular, 33; pneumonia, 26; skin, 15; other, 15.
h ICU, intensive care unit.
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respectively, and the 30-day mortality rates were 10.9%, 12.5%,
12.5%, 15.6%, and 6.5%, respectively.
Kaplan-Meier mortality curves are shown in Fig. 2C. The re-
sults of univariate analysis for cure/improvement and 30-day
mortality are shown in Tables S10 and S11 in the supplemental
material. In the multivariate logistic regression models, and after
controlling for propensity score and other variables, empirical
and targeted therapy with carbapenems showed no significant
effects on cure/improvement rates at day 14 or on mortality
rates compared to the rates in any of the other groups (Tables 2
and 3). Adding individual or grouped centers did not change
the results.
DISCUSSION
Our results strongly support the hypothesis that active BLBLIs
are not inferior to carbapenems for the treatment of BSI due to
ESBL-E in different clinical scenarios. Importantly, these data
not only support previous data on BSI due to E. coli with a
urinary and biliary tract source (11) but also suggest that
BLBLIs may, if active in vitro, be useful alternatives to carbap-
enems for the treatment of BSI due to any ESBL-E from any
source if used at appropriate doses. Our data refer to suscepti-
ble isolates, which is clearly relevant for targeted therapy; how-
ever, it is also relevant for empirical decisions in which an
evaluation of the patient’s individual risk for ESBL producers
and the local epidemiology data on susceptibility of ESBL pro-
ducers to BLBLIs are to be taken into account.
BLBLIs have been shown to be as effective as carbapenems for
the treatment of diverse severe infections in randomized trials
(21). The reasons for raising doubts about the efficacy of BLBLIs in
the treatment of severe infections caused by ESBL-E include the fol-
TABLE 2 Multivariate analysis for cure/improvement in the empirical-therapy, targeted-therapy, and global cohorts
Variable Adjusted OR (95% CI) P value
Empirical-therapy cohort
Age (per unita) 0.98 (0.96–1.00) 0.07
Source
Urinary Reference for comparison
Biliary tract 0.69 (0.24–2.15) 0.51
Other (high-risk source) 0.30 (0.15–0.59) 0.0006
McCabe classification, nonfatal 2.64 (1.40–5.16) 0.003
Pitt score (per unit) 0.79 (0.69–0.90) 0.0003
Severe sepsis or shock 0.25 (0.12–0.50) 0.0001
Empirical therapy with a BLBLI 1.37 (0.69–2.76) 0.37




Biliary tract 0.88 (0.34–2.48) 0.80
Other (high-risk source) 0.40 (0.22–0.71) 0.002
McCabe classification, nonfatal 3.56 (2.00–6.61) 0.0001
Pitt score (per unit) 0.80 (0.71–0.89) 0.0001
Severe sepsis or shock 0.34 (0.19–0.61) 0.0004
Empirical therapy
Activeb Reference
Inactivec/no drugd 0.64 (0.37–1.11) 0.11
Targeted therapy with a BLBLI 1.61 (0.58–4.86) 0.38




Biliary tract 0.55 (0.24–1.30) 0.16
Other (high-risk source) 0.38 (0.20–0.70) 0.002
McCabe classification, nonfatal 3.23 (1.83–5.93) 0.0001
Pitt score (per unit) 0.83 (0.74–0.94) 0.002
Severe sepsis or shock 0.32 (0.17–0.58) 0.0002
Drug used for empirical therapy-drug used for targeted therapy
Carbapenem-carbapenem Reference
BLBLI-carbapenem 0.86 (0.28–2.53) 0.78
BLBLI-BLBLI 1.33 (0.43–4.46) 0.63
Other drug-carbapenem 0.83 (0.28–2.40) 0.74
Other drug-BLBLI 1.37 (0.26–8.85) 0.72
Propensity score 0.99 (0.23–4.21) 0.99
a Per unit of the score.
b Carbapenems, 145; BLBLIs, 134; combined therapy, 69; other, 21.
c Cephalosporin, 93; BLBLIs, 62; ciprofloxacin, 25; combined therapy, 20; other, 17.
d Fifteen cases received no drug.
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lowing. First, the observation that PTZ (but not AMC) is less active in
vitro when tested against a high inoculum of bacteria (22). However,
such an effect also occurs in non-ESBL producers. Second, the results
from some animal data suggesting a lower efficacy than for carbap-
enems against isolates producing TEM-type ESBLs (23, 24) and some
anecdotal failures (25). And third, the fact that the MICs of carbap-
enems (except ertapenem) are usually several dilutions below the
breakpoints, while those of BLBLIs are frequently nearer the break-
point (1, 26). In fact, a specific analysis suggested that PTZ may be less
effective in patients with severe non-urinary tract bacteremic infec-
tions caused by borderline-susceptible ESBL-producing E. coli (27).
Interest in BLBLIs was raised when a post hoc analysis in patients
with BSI due to ESBL-producing E. coli (mostly from the urinary
and biliary tracts) (11) and a recent meta-analysis of mostly small
observational studies could not show that empirical or targeted
therapy with BLBLIs was associated with worse outcomes than
carbapenems (12). Interestingly, however, a recent retrospective
study from one center showed lower survival among patients
treated with BLBLIs (13).
This is an observational study, and thus, the typical limitations
of this design apply, including lack of randomization, the poten-
tial effects of unmeasured variables, and residual confounding
(14). Although this study has, to the best of our knowledge, the
biggest sample size published to date, its statistical power is still
limited and cannot exclude a potential relevant difference be-
tween carbapenems and BLBLIs. Additionally, we could not study
the real exposure to the drugs used because drug levels were not
measured. However, the data reflect clinical practice. Neverthe-
less, this study has some methodological strengths, which should
be taken into consideration. The hypothesis, design, and statistical
analysis plan were preregistered so as to avoid casual post hoc find-
ings, as recommended for observational studies (14, 28, 29). Very
strict criteria for the assignment of treatments were applied. Treat-
ment changes are frequent in real life, making it difficult to assign
patients appropriately to a specific antibiotic in observational
studies; in fact, most observational studies lack appropriate crite-
ria for assignment (14). We used clinical response and mortality as
the main outcome measures. Previous studies mainly evaluated
FIG 1 Adjusted odds ratios and 95% confidence intervals for cure/improvement at day 14 for empirical (A) and targeted (B) therapy with BLBLIs versus
carbapenems in different subgroups.
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mortality, which has the advantage of being a “hard” outcome but
may underestimate differences between drugs; we therefore also
used clinical response, a “softer” but probably more sensitive out-
come measure. Finally, we used advanced methods to control for
confounding and center effects (14). Other strengths of our study
are the inclusion of cases from diverse geographical locations, with
infections caused by non-E. coli species, and with non-urinary
tract sources. A randomized controlled trial would be the best way
to demonstrate that BLBLIs are noninferior to carbapenems; the
MERINO trial, now recruiting in Australia, Singapore, and New
Zealand, will compare PTZ and meropenem in the treatment of
BSI due to ESBL-E (Australian New Zealand Clinical Trials Reg-
istry no. ACTRN12613000532707; https://www.anzctr.org.au
/Trial/Registration/TrialReview.aspx?id363706).
The rates of susceptibility of ESBL-E to BLBLIs are heteroge-
neous, depending on the species and geographical location (6–11,
30, 31). Therefore, local susceptibility patterns of ESBL-E must be
considered. However, ESBL-E are frequently susceptible to PTZ in
many areas of the world. Our data among the patients treated
empirically with PTZ and AMC are similar to the rates of suscep-
FIG 2 Kaplan-Meier curves for mortality in the empirical-therapy cohort (A), the targeted-therapy cohort (B), and the global cohort (C) according to treatment
regimens.
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tibility reported by other authors (frequently higher than 70% for
PTZ [6–10] and higher than 60% for AMC [11, 30]). Finally, these
results encourage the further investigation of newer BLBLI com-
binations that are active even against some carbapenemase-pro-
ducing Enterobacteriaceae. One issue of importance is whether
PTZ and AMC are equally effective. As stated above, AMC does
not suffer from inoculum effect (22) and showed better activity
than PTZ in an experimental murine sepsis model caused by
ESBL-producing E. coli (32). Subgroup analyses did not show dif-
ferences when PTZ or AMC alone was compared to carbapenems.
However, more data are needed to investigate the comparative
efficacies of AMC and PTZ. Of note, whether PTZ has any advan-
tage over ertapenem as a selector for carbapenemase producers is
debatable and should be studied specifically.
Klebsiella pneumoniae was independently associated with
higher mortality than E. coli in adjusted analysis both in the
TABLE 3 Multivariate analysis for 30-day mortality in the empirical-therapy, targeted-therapy, and global cohorts
Variable Adjusted OR (95% CI) P valuea
Empirical-therapy cohort
Age (per unita) 1.05 (1.02–1.07) 0.0006
Source 4.98 (2.37–10.96) 0.0001
Urinary tract Reference for comparison
Biliary tract 1.38 (0.37–4.64) 0.61
Other (high-risk source) 4.50 (2.13–9.98) 0.0001
McCabe classification, nonfatal 0.31 (0.14–0.62) 0.002
Pitt score (per unit) 1.31 (1.14–1.51) 0.0001
Severe sepsis or shock 6.76 (3.11–15.55) 0.0001
Empirical therapy with a BLBLI 0.55 (0.25–1.18) 0.14
Propensity score 1.32 (0.28–6.23) 6.26
Targeted-therapy cohort
Age (per unit) 1.03 (1.01–1.05) 0.003
Enterobacteriaceae species
E. coli Reference
K. pneumoniae 1.96 (0.96–3.42) 0.04
Other 0.91 (0.30–2.51) 0.87
Source
Urinary tract Reference
Biliary tract 0.93 (0.30–2.53) 0.89
Other (high-risk source) 2.89 (1.55–5.55) 0.001
McCabe classification, nonfatal 0.23 (0.12–0.43) 0.0001
Pitt score (per unit) 1.31 (1.16–1.48) 0.0001
Severe sepsis or shock 2.99 (1.62–5.61) 0.0005
Empirical therapy
Active Reference
No active or no empirical therapy 1.82 (1.01–3.28) 0.04
Targeted therapy with a BLBLI 0.59 (0.19–1.71) 0.35
Propensity score 1.17 (0.24–5.30) 0.84
Global cohort
Age (per unit) 1.04 (1.02–1.06) 0.0003
Enterobacteriaceae species
E. coli Reference
K. pneumoniae 2.00 (1.01–3.88) 0.04
Other 1.04 (0.33–2.89) 0.94
Source
Urinary tract Reference
Biliary tract 1.17 (0.44–2.91) 0.75
Other (high-risk source) 2.91 (1.54–5.66) 0.001
McCabe classification, nonfatal 0.24 (0.12–0.45) 0.0001
Pitt score (per unit) 1.25 (1.10–1.42) 0.0004
Severe sepsis or shock 3.45 (1.82–6.70) 0.0002
Drug used for empirical therapy-drug used for targeted therapy
Carbapenem-carbapenem Reference
BLBLI-carbapenem 0.70 (0.21–2.34) 0.56
BLBLI-BLBLI 0.73 (0.20–2.42) 0.61
Other drug-carbapenem 1.16 (0.37–3.76) 0.79
Other drug-BLBLI 0.24 (0.02–1.67) 0.18
Propensity score 0.54 (0.10–2.70) 0.46
a Per unit of the score.
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targeted-therapy cohort and in the global-therapy cohort. Even
though analyzing the impacts of specific bacteria was not an
objective of this study, we think this merits further pathogenic-
ity studies; also, this should be considered in any future out-
come analysis of infections that includes different Enterobacte-
riaceae.
Until the results of randomized control trials are available,
these data are the best evidence available to support the use
of BLBLIs with in vitro activity as alternatives to carbapenems
for the treatment of BSI due to ESBL-E, which may have
significant implications for avoidance of the overuse of carbap-
enems.
TABLE 4 Stratified analysis of outcomes of patients in the empirical- and targeted-therapy cohorts treated with -lactam/-lactam inhibitor
combinations or carbapenems, according to quartiles of the propensity score
Cohort, PS quartile
No. of patients with indicated outcome/no. of patients that received indicated treatment (%)
Cure/improvement Mortality
BLBIs Carbapenems P value BLBIs Carbapenems P value
Empirical therapy
n  170 n  195 n  170 n  195
1st 7/12 (58.3) 59/76 (77.6) 0.15 4/12 (33.3) 18/76 (23.7) 0.47
2nd 29/35 (82.9) 51/59 (86.4) 0.76 5/35 (14.3) 6/59 (10.1) 0.78
3rd 38/50 (76.0) 31/41 (75.6) 0.96 9/50 (18.0) 10/41 (24.4) 0.62
4th 62/73 (84.9) 13/19 (68.4) 0.10 12/73 (16.4) 5/19 (26.3) 0.32
Targeted therapy
n  92 n  509 n  92 n  509
1st 0 127/150 (84.7) 0 21/150 (14.0)
2nd 2/3 (66.7) 128/147 (87.1) 0.30 1/3 (33.3) 19/147 (12.9) 0.30
3rd 13/13 (100.0) 115/137 (83.9) 0.12 0/13 (0.0) 21/137 (15.3) 0.13
4th 68/76 (89.5) 65/75 (86.7) 0.77 8/76 (10.5) 10/75 (13.3) 0.62
TABLE 5 Characteristics of patients with bloodstream infections caused by extended-spectrum--lactamase-producing Enterobacteriaceae in the
global therapy cohort
Characteristic











Age [median (IQRb)] 65 (50.8–75.0) 71.5 (58.0–80.3)c 67
(59.5–76.5)
68 (55.0–79.0)c 74 (56.0–83.5)c
Male sex 96 (61.5) 84 (55.3) 37 (58.7) 129 (57.3) 18 (58.1)
Enterobacteriaceae species
E. coli 113 (72.4) 106 (69.7) 50 (79.4) 170 (75.6) 23 (74.2)
K. pneumoniae 34 (21.8) 34 (22.4) 9 (14.3) 35 (15.6) 5 (16.1)
Other 9 (5.8) 12 (7.9) 4 (6.3) 20 (8.9) 3 (9.7)
Nosocomial acquisition 74 (47.4) 67 (44.1) 27 (42.9) 109 (48.4) 12 (38.7)
Source
Urinary tract 81 (51.9) 59 (38.8) 27 (42.9) 103 (45.8) 15 (48.4)
Biliary tract 25 (16.0) 40 (26.3) 10 (15.9) 17 (7.6) 2 (6.5)
Other (high-risk source) 50 (32.1) 53 (34.9)c 26 (41.3) 105 (46.7)c 14 (45.2)
ICUd admission 19 (12.2) 17 (11.2) 2 (3.2)c 27 (12.0) 2 (6.5)
McCabe classification, nonfatal 76 (48.7) 83 (54.6) 30 (47.6) 108 (48.0) 15 (48.4)
Pitt score [median (IQR)] 1 (0–3) 1 (0–2.25) 1 (0–2) 1 (0–2) 1 (0–2)
Severe sepsis or shock 54 (34.6) 56 (36.8) 25 (39.7) 70 (31.1) 8 (25.8)
Cancer 67 (42.9) 57 (37.5) 30 (47.6) 97 (43.1) 13 (41.9)
Active empirical therapy 156 (100) 96 (63.2)c 58 (92.1) c 78 (34.7)c 10 (32.3)c
Cure/improvement 137 (87.8) 130 (85.5) 55 (87.3) 191 (84.9) 28 (90.3)
30-day mortality 17 (10.9) 19 (12.5) 8 (12.7) 35 (15.6) 2 (6.5)
a The carbapenem-carbapenem group was considered the reference group for comparisons.
b IQR, interquartile range.
c The variable showed a P value of 0.05 in crude analysis.
d ICU, intensive care unit.
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